UnknownNot Applicable

Rheohemapheresis and Lutein Supplementation in the Non-Exsudative Form of Age-Related Macular Degeneration

Austria20 participantsStarted 2007-03

Plain-language summary

Age-related macular degeneration is one of the major causes of blindness in the western world. There is an exsudative and a non-exsudative form of age-related macular degeneration.Most studies concentrate on the exsudative form. In the non-exsudative form the policy is generally watch and see, but patients are at risk to develop an exsudative form. So far, the only accepted therapy to reach stable disease in the non-exsudative form is high-dose supplementation of antioxidants. Another approach to improve visual acuity in patients with non-exsudative form of macular degeneration is rheohemapheresis treatment, an extracorporeal therapy where plasma is separated from blood cells. By the use of a hollow fiber filter plasma is depleted of high molecular weight proteins and reinfused. Others report describe the supplementation of lutein (a vitamin A derivative) as possible treatment option. However, none of the studies have yet examined a combination of rheohemapheresis and lutein supplementation.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Study eye with non-exsudative AMD AREDS II - III * with \> 10 large soft, and / or confluent drusen within 3000 nm of the foveal centre * and a best corrected visual acuity of 0.06 - 1.0 using ETDRS charts (letter score of 3 to 50 letters) * with / without geographic atrophy less than 3 disc diameters within 3000 nm of the foveal centre ´. with / without serous pigment epithelial detachment without clearly identifiable neovascularisation * Patients must have elevated baseline concentrations of at least one of the rheologic parameters (serum cholesterol level \> 200 mg/dL, fibrinogen level \> 390 mg/dL, or plasmaviscosity \> 1.6 mPa\*s) * Men or women aged between 50 - 99 years. Exclusion Criteria: * Study eye with exsudative AMD * Study eye with concomitant retinal or choroidal disorder other than AMD * Study eye with significant central lens opacities and / or conditions that limit the view of the fundus * poor general condition * hematocrit \< 30% * coagulation disorders (incl. marcoumar therapy) * significant cardiac problems ( \> NYHA II) * history (\< 12 months) of cardiac infarction * uncontrolled arterial hypertension * recent history (\< 3 months) of cerebral vascular infarction * cerebrovascular disease IV * uncontrolled diabetes * insufficient antecubital venous access * lutein supplementation within the last 3 months * weight \< 45 kg * hemato-oncological disorder * Patients who are unwilling to adhere to visit examination schedules

Trial details

NCT IDNCT00443911

SponsorThe Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Sponsor typeOTHER

Study typeOBSERVATIONAL

View on ClinicalTrials.gov More Age-related Macular Degeneration trials